protocolSection identificationModule nctId: NCT06260254, orgStudyIdInfo id: 244826201, briefTitle: Effects of Railway Vibration on Sleep and Disease, acronym: BioVib, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-05, primaryCompletionDateStruct date: 2024-06-30, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: Göteborg University, class: OTHER, collaborators name: University of Pennsylvania, collaborators name: University of Manitoba, descriptionModule briefSummary: This study will investigate the biological mechanisms linking sleep disruption by vibration and noise, and the development of cardiometabolic disease. In a laboratory sleep study, the investigators will play railway vibration of different levels during the night. The investigators will also measure objective sleep quality and quantity, cognitive performance across multiple domains, self-reported sleep and wellbeing outcomes, and blood samples. Blood samples will be analyzed to identify metabolic changes and indicators of diabetes risk in different nights. Identifying biomarkers that are impacted by sleep fragmentation will establish the currently unclear pathways by which railway vibration exposure at night can lead to the development of diseases in the long term, especially metabolic disorders including diabetes., conditionsModule conditions: Noise Exposure, conditions: Sleep Disturbance, conditions: Sleep Hygiene, conditions: Metabolic Disturbance, conditions: Cognitive Change, conditions: Glucose Metabolism Disorders (Including Diabetes Mellitus), conditions: Vibration; Exposure, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, interventionModelDescription: All participants will be exposed to each of the different vibration conditions. Each study night is treated as a separate arm of the crossover study. The order of the vibration exposure conditions will be be randomly assigned across participants using a Latin square design to avoid first-order carryover effects. Each subject will be exposed to one night of each of the following:Quiet night: No noise or vibration will be played, serving as a control night to assess individual baseline sleep, metabolic profile, and cognitive performance; Three railway vibration nights to determine consequences of noise-disrupted sleep. The vibration level in these three nights will be 0.5 mm/s, 0.7 mm/s and 0.9 mm/s respectively, so that exposure-response relationships can be derived., primaryPurpose: BASIC_SCIENCE, maskingInfo masking: DOUBLE, maskingDescription: Participants will be aware that in any given study night they can be exposed to railway vibration and noise. They will not be informed what exposure condition will occur in any given night, but they can become unblinded to the exposure if they are awake, as they will may hear the noise or feel the vibration.Study investigators responsible for analysing cognitive performance variables and physiological sleep data will be be blind to which vibration and noise interventions were introduced on which study nights., whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 24, type: ESTIMATED, armsInterventionsModule interventions name: Railway noise, interventions name: Low level railway vibration, interventions name: Intermediate level railway vibration, interventions name: High level railway vibration, outcomesModule primaryOutcomes measure: Fasting insulin resistance in the morning immediately after the Control night, primaryOutcomes measure: Fasting insulin resistance in the morning immediately after the low vibration night, primaryOutcomes measure: Fasting insulin resistance in the morning immediately after the intermediate vibration night, primaryOutcomes measure: Fasting insulin resistance in the morning immediately after the high vibration night, primaryOutcomes measure: Total sleep time during the Control night, primaryOutcomes measure: Total sleep time during the low vibration night, primaryOutcomes measure: Total sleep time during the intermediate vibration night, primaryOutcomes measure: Total sleep time during the high vibration night, primaryOutcomes measure: Total amount of N1 sleep during the Control night, primaryOutcomes measure: Total amount of N2 sleep during the Control night, primaryOutcomes measure: Total amount of N3 sleep during the Control night, primaryOutcomes measure: Total amount of rapid eye movement (REM) sleep during the Control night, primaryOutcomes measure: Total amount of N1 sleep during the low vibration night, primaryOutcomes measure: Total amount of N2 sleep during the low vibration night, primaryOutcomes measure: Total amount of N3 sleep during the low vibration night, primaryOutcomes measure: Total amount of rapid eye movement (REM) sleep during the low vibration night, primaryOutcomes measure: Total amount of N1 sleep during the intermediate vibration night, primaryOutcomes measure: Total amount of N2 sleep during the intermediate vibration night, primaryOutcomes measure: Total amount of N3 sleep during the intermediate vibration night, primaryOutcomes measure: Total amount of rapid eye movement (REM) sleep during the intermediate vibration night, primaryOutcomes measure: Total amount of N1 sleep during the high vibration night, primaryOutcomes measure: Total amount of N2 sleep during the high vibration night, primaryOutcomes measure: Total amount of N3 sleep during the high vibration night, primaryOutcomes measure: Total amount of rapid eye movement (REM) sleep during the high vibration night, primaryOutcomes measure: Wakefulness after sleep onset (WASO) during the Control night, primaryOutcomes measure: Wakefulness after sleep onset (WASO) during the low vibration night, primaryOutcomes measure: Wakefulness after sleep onset (WASO) during the intermediate night, primaryOutcomes measure: Wakefulness after sleep onset (WASO) during the high vibration night, primaryOutcomes measure: Number of awakenings during the Control night, primaryOutcomes measure: Number of awakenings during exposure to low vibration, primaryOutcomes measure: Number of awakenings during exposure to intermediate vibration, primaryOutcomes measure: Number of awakenings during exposure to high vibration, primaryOutcomes measure: Sleep onset latency (SOL) during the Control Night, primaryOutcomes measure: Sleep onset latency (SOL) during the low vibration night, primaryOutcomes measure: Sleep onset latency (SOL) during the intermediate vibration night, primaryOutcomes measure: Sleep onset latency (SOL) during the high vibration night, primaryOutcomes measure: Sleep efficiency during the Control night, primaryOutcomes measure: Sleep efficiency during the low vibration night, primaryOutcomes measure: Sleep efficiency during the intermediate vibration night, primaryOutcomes measure: S Sleep efficiency during the high vibration night, primaryOutcomes measure: Sleep depth assessed using the odds ratio product (ORP) during the Control night, primaryOutcomes measure: Sleep depth assessed using the odds ratio product (ORP) during the low vibration night, primaryOutcomes measure: Sleep depth assessed using the odds ratio product (ORP) during the intermediate vibration night, primaryOutcomes measure: Sleep depth assessed using the odds ratio product (ORP) during the high vibration night, primaryOutcomes measure: Maximal change of odds ratio product (ORP) during exposure to railway vibration events, primaryOutcomes measure: Area under the curve of odds ratio product (ORP) during exposure to railway vibration events, calculated using the trapezoid rule, primaryOutcomes measure: N-acetylglucosamine/galactosamine (GlycA) concentration after the Control night, primaryOutcomes measure: N-acetylglucosamine/galactosamine (GlycA) concentration after exposure to low vibration night, primaryOutcomes measure: N-acetylglucosamine/galactosamine (GlycA) concentration after exposure to intermediate vibration, primaryOutcomes measure: N-acetylglucosamine/galactosamine (GlycA) concentration after exposure to high vibration, primaryOutcomes measure: Sialic acid (GlycB) concentration after the Control night, primaryOutcomes measure: Sialic acid (GlycB) concentration after exposure to low vibration, primaryOutcomes measure: Sialic acid (GlycB) concentration after exposure to intermediate vibration, primaryOutcomes measure: Sialic acid (GlycB) concentration after exposure to high vibration, primaryOutcomes measure: Supramolecular phospholipid composite (SPC) concentration after the Control night, primaryOutcomes measure: Supramolecular phospholipid composite (SPC) concentration after exposure to low vibration, primaryOutcomes measure: Supramolecular phospholipid composite (SPC) concentration after exposure to intermediate vibration, primaryOutcomes measure: Supramolecular phospholipid composite (SPC) concentration after exposure to high vibration, primaryOutcomes measure: Ethanol concentration (mmol/L) after the Control night, primaryOutcomes measure: Ethanol concentration (mmol/L) after exposure to low vibration night, primaryOutcomes measure: Ethanol concentration (mmol/L) after exposure to intermediate vibration night, primaryOutcomes measure: Ethanol concentration (mmol/L) after exposure to high vibration night, primaryOutcomes measure: Trimethylamine-N-oxide concentration (mmol/L) after exposure to Control night, primaryOutcomes measure: Trimethylamine-N-oxide concentration (mmol/L) after exposure to low vibration night, primaryOutcomes measure: Trimethylamine-N-oxide concentration (mmol/L) after exposure to intermediate vibration night, primaryOutcomes measure: Trimethylamine-N-oxide concentration (mmol/L) after exposure to high vibration night, primaryOutcomes measure: 2-Aminobutyric acid concentration (mmol/L) after exposure to Control night, primaryOutcomes measure: 2-Aminobutyric acid concentration (mmol/L) after exposure to low vibration night, primaryOutcomes measure: 2-Aminobutyric acid concentration (mmol/L) after exposure to intermediate vibration night, primaryOutcomes measure: 2-Aminobutyric acid concentration (mmol/L) after exposure to high vibration night, primaryOutcomes measure: Alanine concentration (mmol/L) after exposure to Control night, primaryOutcomes measure: Alanine concentration (mmol/L) after exposure to low vibration night, primaryOutcomes measure: Alanine concentration (mmol/L) after exposure to intermediate vibration night, primaryOutcomes measure: Alanine concentration (mmol/L) after exposure to high vibration night, primaryOutcomes measure: Asparagine concentration (mmol/L) after exposure to Control night, primaryOutcomes measure: Asparagine concentration (mmol/L) after exposure to low vibration night, primaryOutcomes measure: Asparagine concentration (mmol/L) after exposure to intermediate vibration night, primaryOutcomes measure: Asparagine concentration (mmol/L) after exposure to high vibration night, primaryOutcomes measure: Creatine concentration (mmol/L) after exposure to Control night, primaryOutcomes measure: Creatine concentration (mmol/L) after exposure to low vibration night, primaryOutcomes measure: Creatine concentration (mmol/L) after exposure to intermediate vibration night, primaryOutcomes measure: Creatine concentration (mmol/L) after exposure to high vibration night, primaryOutcomes measure: Creatinine concentration (mmol/L) after exposure to Control night, primaryOutcomes measure: Creatinine concentration (mmol/L) after exposure to low vibration night, primaryOutcomes measure: Creatinine concentration (mmol/L) after exposure to intermediate vibration night, primaryOutcomes measure: Creatinine concentration (mmol/L) after exposure to high vibration night, primaryOutcomes measure: Glutamic acid concentration (mmol/L) after exposure to Control night, primaryOutcomes measure: Glutamic acid concentration (mmol/L) after exposure to low vibration night, primaryOutcomes measure: Glutamic acid concentration (mmol/L) after exposure to intermediate vibration night, primaryOutcomes measure: Glutamic acid concentration (mmol/L) after exposure to high vibration night, primaryOutcomes measure: Glutamine concentration (mmol/L) after exposure to Control night, primaryOutcomes measure: Glutamine concentration (mmol/L) after exposure to low vibration night, primaryOutcomes measure: Glutamine concentration (mmol/L) after exposure to intermediate vibration night, primaryOutcomes measure: Glutamine concentration (mmol/L) after exposure to high vibration night, primaryOutcomes measure: Glycine concentration (mmol/L) after exposure to Control night, primaryOutcomes measure: Glycine concentration (mmol/L) after exposure to low vibration night, primaryOutcomes measure: Glycine concentration (mmol/L) after exposure to intermediate vibration night, primaryOutcomes measure: Glycine concentration (mmol/L) after exposure to high vibration night, primaryOutcomes measure: Histidine concentration (mmol/L) after exposure to Control night, primaryOutcomes measure: Histidine concentration (mmol/L) after exposure to low vibration night, primaryOutcomes measure: Histidine concentration (mmol/L) after exposure to intermediate vibration night, primaryOutcomes measure: Histidine concentration (mmol/L) after exposure to high vibration night, primaryOutcomes measure: Isoleucine concentration (mmol/L) after exposure to Control night, primaryOutcomes measure: Isoleucine concentration (mmol/L) after exposure to low vibration night, primaryOutcomes measure: Isoleucine concentration (mmol/L) after exposure to intermediate vibration night, primaryOutcomes measure: Isoleucine concentration (mmol/L) after exposure to high vibration night, primaryOutcomes measure: Leucine concentration (mmol/L) after exposure to Control night, primaryOutcomes measure: Leucine concentration (mmol/L) after exposure to low vibration night, primaryOutcomes measure: Leucine concentration (mmol/L) after exposure to intermediate vibration night, primaryOutcomes measure: Leucine concentration (mmol/L) after exposure to high vibration night, primaryOutcomes measure: Lysine concentration (mmol/L) after exposure to Control night, primaryOutcomes measure: Lysine concentration (mmol/L) after exposure to low vibration night, primaryOutcomes measure: Lysine concentration (mmol/L) after exposure to intermediate vibration night, primaryOutcomes measure: Lysine concentration (mmol/L) after exposure to high vibration night, primaryOutcomes measure: Methionine concentration (mmol/L) after exposure to Control night, primaryOutcomes measure: Methionine concentration (mmol/L) after exposure to low vibration night, primaryOutcomes measure: Methionine concentration (mmol/L) after exposure to intermediate vibration night, primaryOutcomes measure: Methionine concentration (mmol/L) after exposure to high vibration night, primaryOutcomes measure: N,N-Dimethylglycine concentration (mmol/L) after Control night, primaryOutcomes measure: N,N-Dimethylglycine concentration (mmol/L) after exposure to low vibration night, primaryOutcomes measure: N,N-Dimethylglycine concentration (mmol/L) after exposure to intermediate vibration night, primaryOutcomes measure: N,N-Dimethylglycine concentration (mmol/L) after exposure to high vibration night, primaryOutcomes measure: Ornithine concentration (mmol/L) after exposure to Control night, primaryOutcomes measure: Ornithine concentration (mmol/L) after exposure to low vibration night, primaryOutcomes measure: Ornithine concentration (mmol/L) after exposure to intermediate vibration night, primaryOutcomes measure: Ornithine concentration (mmol/L) after exposure to high vibration night, primaryOutcomes measure: Phenylalanine concentration (mmol/L) after exposure to Control night, primaryOutcomes measure: Phenylalanine concentration (mmol/L) after exposure to low vibration night, primaryOutcomes measure: Phenylalanine concentration (mmol/L) after exposure to intermediate vibration night, primaryOutcomes measure: Phenylalanine concentration (mmol/L) after exposure to high vibration night, primaryOutcomes measure: Proline concentration (mmol/L) after exposure to Control night, primaryOutcomes measure: Proline concentration (mmol/L) after exposure to low vibration night, primaryOutcomes measure: Proline concentration (mmol/L) after exposure to intermediate vibration night, primaryOutcomes measure: Proline concentration (mmol/L) after exposure to high vibration night, primaryOutcomes measure: Sarcosine concentration (mmol/L) after exposure to Control night, primaryOutcomes measure: Sarcosine concentration (mmol/L) after exposure to low vibration night, primaryOutcomes measure: Sarcosine concentration (mmol/L) after exposure to intermediate vibration night, primaryOutcomes measure: Sarcosine concentration (mmol/L) after exposure to high vibration night, primaryOutcomes measure: Threonine concentration (mmol/L) after exposure to Control night, primaryOutcomes measure: Threonine concentration (mmol/L) after exposure to low vibration night, primaryOutcomes measure: Threonine concentration (mmol/L) after exposure to intermediate vibration night, primaryOutcomes measure: Threonine concentration (mmol/L) after exposure to high vibration night, primaryOutcomes measure: Tyrosine concentration (mmol/L) after exposure toControl night, primaryOutcomes measure: Tyrosine concentration (mmol/L) after exposure to low vibration night, primaryOutcomes measure: Tyrosine concentration (mmol/L) after exposure to intermediate vibration night, primaryOutcomes measure: Tyrosine concentration (mmol/L) after exposure to high vibration night, primaryOutcomes measure: Valine concentration (mmol/L) after Control night, primaryOutcomes measure: Valine concentration (mmol/L) after exposure to low vibration night, primaryOutcomes measure: Valine concentration (mmol/L) after exposure to intermediate vibration night, primaryOutcomes measure: Valine concentration (mmol/L) after exposure to high vibration night, primaryOutcomes measure: 2-Hydroxybutyric acid concentration (mmol/L) after exposure to Control night, primaryOutcomes measure: 2-Hydroxybutyric acid concentration (mmol/L) after exposure to low vibration night, primaryOutcomes measure: 2-Hydroxybutyric acid concentration (mmol/L) after exposure to intermediate vibration night, primaryOutcomes measure: 2-Hydroxybutyric acid concentration (mmol/L) after exposure to high vibration night, primaryOutcomes measure: Acetic acid concentration (mmol/L) after exposure to Control night, primaryOutcomes measure: Acetic acid concentration (mmol/L) after exposure to low vibration night, primaryOutcomes measure: Acetic acid concentration (mmol/L) after exposure to intermediate vibration night, primaryOutcomes measure: Acetic acid concentration (mmol/L) after exposure to high vibration night, primaryOutcomes measure: Citric acid concentration (mmol/L) after Control night, primaryOutcomes measure: Citric acid concentration (mmol/L) after exposure to low vibration night, primaryOutcomes measure: Citric acid concentration (mmol/L) after exposure to intermediate vibration night, primaryOutcomes measure: Citric acid concentration (mmol/L) after exposure to high vibration night, primaryOutcomes measure: Formic acid concentration (mmol/L) after exposure to Control night, primaryOutcomes measure: Formic acid concentration (mmol/L) after exposure to low vibration night, primaryOutcomes measure: Formic acid concentration (mmol/L) after exposure to intermediate vibration night, primaryOutcomes measure: Formic acid concentration (mmol/L) after exposure to high vibration night, primaryOutcomes measure: Lactic acid concentration (mmol/L) after exposure to Control night, primaryOutcomes measure: Lactic acid concentration (mmol/L) after exposure to low vibration night, primaryOutcomes measure: Lactic acid concentration (mmol/L) after exposure to intermediate vibration night, primaryOutcomes measure: Lactic acid concentration (mmol/L) after exposure to high vibration night, primaryOutcomes measure: Succinic acid concentration (mmol/L) after exposure to Control night, primaryOutcomes measure: Succinic acid concentration (mmol/L) after exposure to low vibration night, primaryOutcomes measure: Succinic acid concentration (mmol/L) after exposure to intermediate vibration night, primaryOutcomes measure: Succinic acid concentration (mmol/L) after exposure to high vibration night, primaryOutcomes measure: Choline concentration (mmol/L) after exposure to Control night, primaryOutcomes measure: Choline concentration (mmol/L) after exposure to low vibration night, primaryOutcomes measure: Choline concentration (mmol/L) after exposure to intermediate vibration night, primaryOutcomes measure: Choline concentration (mmol/L) after exposure to high vibration night, primaryOutcomes measure: 2-Oxoglutaric acid concentration (mmol/L) after exposure to Control night, primaryOutcomes measure: 2-Oxoglutaric acid concentration (mmol/L) after exposure to low vibration night, primaryOutcomes measure: 2-Oxoglutaric acid concentration (mmol/L) after exposure to intermediate vibration night, primaryOutcomes measure: 2-Oxoglutaric acid concentration (mmol/L) after exposure to high vibration night, primaryOutcomes measure: 3-Hydroxybutyric acid concentration (mmol/L) after exposure to Control night, primaryOutcomes measure: 3-Hydroxybutyric acid concentration (mmol/L) after exposure to low vibration night, primaryOutcomes measure: 3-Hydroxybutyric acid concentration (mmol/L) after exposure to intermediate vibration night, primaryOutcomes measure: 3-Hydroxybutyric acid concentration (mmol/L) after exposure to high vibration night, primaryOutcomes measure: Acetoacetic acid concentration (mmol/L) after exposure to Control night, primaryOutcomes measure: Acetoacetic acid concentration (mmol/L) after exposure to low vibration night, primaryOutcomes measure: Acetoacetic acid concentration (mmol/L) after exposure to intermediate vibration night, primaryOutcomes measure: Acetoacetic acid concentration (mmol/L) after exposure to high vibration night, primaryOutcomes measure: Acetone concentration (mmol/L) after exposure to Control night, primaryOutcomes measure: Acetone concentration (mmol/L) after exposure to low vibration night, primaryOutcomes measure: Acetone concentration (mmol/L) after exposure to intermediate vibration night, primaryOutcomes measure: Acetone concentration (mmol/L) after exposure to high vibration night, primaryOutcomes measure: Pyruvic acid concentration (mmol/L) after exposure to Control night, primaryOutcomes measure: Pyruvic acid concentration (mmol/L) after exposure to low vibration night, primaryOutcomes measure: Pyruvic acid concentration (mmol/L) after exposure to intermediate vibration night, primaryOutcomes measure: Pyruvic acid concentration (mmol/L) after exposure to high vibration night, primaryOutcomes measure: D-Galactose concentration (mmol/L) after exposure to Control night, primaryOutcomes measure: D-Galactose concentration (mmol/L) after exposure to low vibration night, primaryOutcomes measure: D-Galactose concentration (mmol/L) after exposure to intermediate vibration night, primaryOutcomes measure: D-Galactose concentration (mmol/L) after exposure to high vibration night, primaryOutcomes measure: Glucose concentration (mmol/L) after exposure to Control night, primaryOutcomes measure: Glucose concentration (mmol/L) after exposure to low vibration night, primaryOutcomes measure: Glucose concentration (mmol/L) after exposure to intermediate vibration night, primaryOutcomes measure: Glucose concentration (mmol/L) after exposure to high vibration night, primaryOutcomes measure: Glycerol concentration (mmol/L) after exposure to Control night, primaryOutcomes measure: Glycerol concentration (mmol/L) after exposure to low vibration night, primaryOutcomes measure: Glycerol concentration (mmol/L) after exposure to intermediate vibration night, primaryOutcomes measure: Glycerol concentration (mmol/L) after exposure to high vibration night, primaryOutcomes measure: Dimethylsulfone concentration (mmol/L) after exposure to Control night, primaryOutcomes measure: Dimethylsulfone concentration (mmol/L) after exposure to low vibration night, primaryOutcomes measure: Dimethylsulfone concentration (mmol/L) after exposure to intermediate vibration night, primaryOutcomes measure: Dimethylsulfone concentration (mmol/L) after exposure to high vibration night, primaryOutcomes measure: Response to an oral glucose bolus, calculated as area under curve for glucose, in the morning after the control night, primaryOutcomes measure: Response to an oral glucose bolus, calculated as area under curve for glucose, in the morning after the low vibration night, primaryOutcomes measure: Response to an oral glucose bolus, calculated as area under curve for glucose, in the morning after the intermediate vibration night, primaryOutcomes measure: Response to an oral glucose bolus, calculated as area under curve for glucose, in the morning after the high vibration night, primaryOutcomes measure: Response to an oral glucose load calculated as area under curve for insulin, in the morning after the low vibration night, primaryOutcomes measure: Response to an oral glucose load calculated as area under curve for insulin, in the morning after the intermediate vibration night, primaryOutcomes measure: Response to an oral glucose load calculated as area under curve for insulin, in the morning after the high vibration night, primaryOutcomes measure: Early response to an oral glucose load calculated as area under curve for insulin, in the morning after the control night, primaryOutcomes measure: Early response to an oral glucose load calculated as area under curve for insulin, in the morning after the low vibration night, primaryOutcomes measure: Early response to an oral glucose load calculated as area under curve for insulin, in the morning after the intermediate vibration night, primaryOutcomes measure: Early response to an oral glucose load calculated as area under curve for insulin, in the morning after the high vibration night, primaryOutcomes measure: Glucose tolerance in the morning after exposure to low vibration, assessed as glucose concentration 120 minutes after a glucose bolus, primaryOutcomes measure: Glucose tolerance in the morning after exposure to intermediate vibration, assessed as glucose concentration 120 minutes after a glucose bolus, primaryOutcomes measure: Glucose tolerance in the morning after exposure to high vibration, assessed as glucose concentration 120 minutes after a glucose bolus, primaryOutcomes measure: Glucose tolerance in the morning after Control night, assessed as glucose concentration 120 minutes after a glucose bolus, primaryOutcomes measure: Stumvoll Insulin sensitivity Index in the morning after control, primaryOutcomes measure: Stumvoll Insulin sensitivity Index in the morning after exposure to low vibration, primaryOutcomes measure: Stumvoll Insulin sensitivity Index in the morning after exposure to intermediate vibration, primaryOutcomes measure: Stumvoll Insulin sensitivity Index in the morning after exposure to high vibration, primaryOutcomes measure: Matsuda insulin sensitivity index in the morning after control exposure, primaryOutcomes measure: Matsuda insulin sensitivity index in the morning after exposure to low vibration, primaryOutcomes measure: Matsuda insulin sensitivity index in the morning after exposure to intermediate vibration, primaryOutcomes measure: Matsuda insulin sensitivity index in the morning after exposure to high vibration, secondaryOutcomes measure: Evening subjective sleepiness, assessed using the Karolinska Sleepiness Scale after exposure to control, secondaryOutcomes measure: Evening subjective sleepiness, assessed using the Karolinska Sleepiness Scale after exposure to low vibration, secondaryOutcomes measure: Evening subjective sleepiness, assessed using the Karolinska Sleepiness Scale after exposure to intermediate vibration, secondaryOutcomes measure: Evening subjective sleepiness, assessed using the Karolinska Sleepiness Scale after exposure to high vibration, secondaryOutcomes measure: Morning subjective sleepiness, assessed using the Karolinska Sleepiness Scale after exposure to control, secondaryOutcomes measure: Morning subjective sleepiness, assessed using the Karolinska Sleepiness Scale after exposure to low vibration, secondaryOutcomes measure: Morning subjective sleepiness, assessed using the Karolinska Sleepiness Scale after exposure to intermediate vibration, secondaryOutcomes measure: Morning subjective sleepiness, assessed using the Karolinska Sleepiness Scale after exposure to high vibration, secondaryOutcomes measure: Self-reported sleep disturbance by vibration after control exposure, secondaryOutcomes measure: Self-reported sleep disturbance by vibration after exposure to low vibration, secondaryOutcomes measure: Self-reported sleep disturbance by vibration after exposure to intermediate vibration, secondaryOutcomes measure: Self-reported sleep disturbance by vibration after exposure to high vibration, secondaryOutcomes measure: Morning positive affect, assessed using the Positive and Negative Affect Schedule (PANAS) after control exposure, secondaryOutcomes measure: Morning positive affect, assessed using the Positive and Negative Affect Schedule (PANAS) after exposure to low vibration, secondaryOutcomes measure: Morning positive affect, assessed using the Positive and Negative Affect Schedule (PANAS) after exposure to intermediate vibration, secondaryOutcomes measure: Morning positive affect, assessed using the Positive and Negative Affect Schedule (PANAS) after exposure to high vibration, secondaryOutcomes measure: Morning negative affect, assessed using the Positive and Negative Affect Schedule (PANAS) after control exposure, secondaryOutcomes measure: Morning negative affect, assessed using the Positive and Negative Affect Schedule (PANAS) after exposure to low vibration, secondaryOutcomes measure: Morning negative affect, assessed using the Positive and Negative Affect Schedule (PANAS) after exposure to intermediate vibration, secondaryOutcomes measure: Morning negative affect, assessed using the Positive and Negative Affect Schedule (PANAS) after exposure to high vibration, secondaryOutcomes measure: Evening negative affect, assessed using the Positive and Negative Affect Schedule (PANAS) after exposure to control, secondaryOutcomes measure: Evening negative affect, assessed using the Positive and Negative Affect Schedule (PANAS) after exposure to low vibration, secondaryOutcomes measure: Evening negative affect, assessed using the Positive and Negative Affect Schedule (PANAS) after exposure to intermediate vibration, secondaryOutcomes measure: Evening negative affect, assessed using the Positive and Negative Affect Schedule (PANAS) after exposure to high vibration, secondaryOutcomes measure: Evening positive affect, assessed using the Positive and Negative Affect Schedule (PANAS) after exposure to control, secondaryOutcomes measure: Evening positive affect, assessed using the Positive and Negative Affect Schedule (PANAS) after exposure to low vibration, secondaryOutcomes measure: Evening positive affect, assessed using the Positive and Negative Affect Schedule (PANAS) after exposure to intermediate vibration, secondaryOutcomes measure: Evening positive affect, assessed using the Positive and Negative Affect Schedule (PANAS) after exposure to high vibration, secondaryOutcomes measure: Event-related cardiovascular activation in response to control, secondaryOutcomes measure: Event-related cardiovascular activation in response to low vibration, secondaryOutcomes measure: Event-related cardiovascular activation in response to intermediate vibration, secondaryOutcomes measure: Event-related cardiovascular activation in response to high vibration, secondaryOutcomes measure: Evening neurobehavioural speed, secondaryOutcomes measure: Evening neurobehavioural accuracy, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 30 Years, stdAges: ADULT, contactsLocationsModule locations facility: University of Gothenburg, status: RECRUITING, city: Gothenburg, state: Västra Götaland, zip: 42650, country: Sweden, contacts name: Michael G Smith, PhD, role: CONTACT, phone: +46317862843, email: michael.smith@amm.gu.se, geoPoint lat: 57.70716, lon: 11.96679, hasResults: False